DEPRENYL IN PARKINSON'S DISEASE
Authors:
- A.J. LeesALA.J. Lees
- L.J. KohoutLKL.J. Kohout
- K.M. ShawKSK.M. Shaw
- G.M. SternGSG.M. Stern
- J.D. ElsworthJEJ.D. Elsworth
- M. SandlerMSM. Sandler
- M.B.H. YoudimMYM.B.H. Youdim
- 1 October 1977
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 310 (8042) , 791-795
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASEThe Lancet, 1977
- TRANSITORY DECREASE IN PLATELET MONOAMINE-OXIDASE ACTIVITY DURING MIGRAINE ATTACKSThe Lancet, 1977
- Dopamine is a monoamine oxidase B substrate in manNature, 1977
- "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPYThe Lancet, 1976
- Preferential deamination of dopamine by an A type monoamine oxidase in rat brainNaunyn-Schmiedeberg's Archives of Pharmacology, 1976
- Five Years' Treatment of Parkinson's Disease with LevodopaAnnals of Internal Medicine, 1975
- The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenilJournal of Neural Transmission, 1975
- Monoamine oxidase inhibitors and L-dopa.BMJ, 1970
- Some observations upon a new inhibitor of monoamine oxidase in brain tissueBiochemical Pharmacology, 1968
- Der L-Dioxyphenylalanin (=L-DOPA)-Effekt beim Parkinson-Syndrom des Menschen: Zur Pathogenese und Behandlung der Parkinson-AkineseEuropean Archives of Psychiatry and Clinical Neuroscience, 1962